Montana opens private lane to experimental drugs, sidestepping FDA oversight
Montana has created a privately run board to approve and offer experimental, unapproved drugs to residents, signaling a new 'right-to-try' style approach that seeks to bypass the FDA’s drug development process. Critics warn of potential conflicts of interest and question whether patients will receive real value from treatments lacking rigorous safety and efficacy data.


